0
July 27, 1979, Vol 242, No. 4 >
ARTICLE | July 27, 1979

Mexiletine: Title and subTitle BreakUse in Control of Chronic Drug-Resistant Ventricular Arrhythmia FREE

Edward G. Abinader, MB, BCh, MRCPI; Michael Cooper, MD
[+] Author Affiliations

Reprint requests to Heart Institute, Rothschild University Hospital, PO Box 4940, Haifa, Israel (Dr Abinader).


JAMA. 1979;242(4):337-339. doi:10.1001/jama.1979.03300040023016
Text Size: A A A
Published online
Article
References

The antiarrhythmic efficacy of mexiletine hydrochloride was studied in ten selected patients with stable resistant ventricular ectopic activity in whom lidocaine, procainamide, and other antiarrhythmic agents were of no avail. Continuous Holter ECG tapes were analyzed before, during, and after mexiletine.

Orally administered mexiletine was found to be very effective in treatment of drug-resistant ventricular arrhythmias, with total abolition of arrhythmia in six and satisfactory control in two additional patients. Long-term follow-up confirmed maintenance of antiarrhythmic efficacy, while biochemical and hematological screening demonstrated no abnormalities. The long therapeutic half-life of the drug allowed convenient dosage schedule and good compliance.

Its efficacy, low frequency of side effects, and long half-life make it an agent of notable value in suppressing ventricular arrhythmias.

(JAMA 242:337-339, 1979)

REFERENCES

1 +
Talbot RG, Clarke RA, Nimmo J, et al:  Treatment of ventricular arrhythmias with mexiletine (Kö 1173) . Lancet 2:399-403, 1973;.
2 +
Campbell NPS, Chaturvedi NC, Kelly JG, et al:  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias . Lancet 2:404-407, 1973;.
3 +
Lellouche D, Bougherbal R: La mexiletine:  Action sur les troubles du rhythme cardiaque . Nouv Presse Med 4:351-352, 1975;.
4 +
Achuff SC, Campbell RWF, Pottage A, et al:  Mexiletine in the prevention of ventricular dysrhythmias in acute myocardial infarction . Circulation 51/52( (suppl 2) ):147, 1975;.
5 +
Talbot RG, Julian DG, Prescott LF:  Long-term treatment of ventricular arrhythmias with oral mexiletine . Am Heart J 91:58-65, 1976;.
6 +
Campbell RWF, Julian DG, Talbot RG, et al:  Long-term treatment of ventricular arrhythmias with oral mexiletine . Postgrad Med J 53( (suppl 1) ):146-148, 1977;.
7 +
Campbell RWF, Dolder MA, Prescott LF, et al:  Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction . Lancet 1:1257-1259, 1975;.
8 +
Jewitt D, McComish M, Jackson G:  Controlled comparison of mexiletine, procainamide and tolamolol in ventricular arrhythmias complicating coronary artery disease . Circulation 51/52( (suppl 2) ):199, 1975;.
9 +
Willox S, Sing BN:  Pharmacology and pharmacokinetics of mexiletine (Kö 1173) . NZ Med J 8:138-141, 1975;.
10 +
Kosowsky BD, Taylor J, Lown B, et al:  Long-term use of procainamide following acute myocardial infarction . Circulation 47:1204-1210, 1973;.
11 +
Selzer A, Wray HW:  Quinidine syncopeparoxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias . Circulation 30:17-26, 1964;.
12 +
Elliott WC, Stone JM:  β-Adrenergic blocking agents for the treatment of angina pectoris . Prog Cardiovasc Dis 12:83-98, 1969;.
13 +
Fitzgerald JD:  β-Adrenergic blocking drugs: Present position and future development . Acta Cardiol 15( (suppl) ):199, 1972;.
14 +
Stone N, Klein MD, Lown B:  Diphenylhydantoin in the prevention of recurring ventricular tachycardia . Circulation 43:420-427, 1971;.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Talbot RG, Clarke RA, Nimmo J, et al:  Treatment of ventricular arrhythmias with mexiletine (Kö 1173) . Lancet 2:399-403, 1973;.
2 +
Campbell NPS, Chaturvedi NC, Kelly JG, et al:  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias . Lancet 2:404-407, 1973;.
3 +
Lellouche D, Bougherbal R: La mexiletine:  Action sur les troubles du rhythme cardiaque . Nouv Presse Med 4:351-352, 1975;.
4 +
Achuff SC, Campbell RWF, Pottage A, et al:  Mexiletine in the prevention of ventricular dysrhythmias in acute myocardial infarction . Circulation 51/52( (suppl 2) ):147, 1975;.
5 +
Talbot RG, Julian DG, Prescott LF:  Long-term treatment of ventricular arrhythmias with oral mexiletine . Am Heart J 91:58-65, 1976;.
6 +
Campbell RWF, Julian DG, Talbot RG, et al:  Long-term treatment of ventricular arrhythmias with oral mexiletine . Postgrad Med J 53( (suppl 1) ):146-148, 1977;.
7 +
Campbell RWF, Dolder MA, Prescott LF, et al:  Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction . Lancet 1:1257-1259, 1975;.
8 +
Jewitt D, McComish M, Jackson G:  Controlled comparison of mexiletine, procainamide and tolamolol in ventricular arrhythmias complicating coronary artery disease . Circulation 51/52( (suppl 2) ):199, 1975;.
9 +
Willox S, Sing BN:  Pharmacology and pharmacokinetics of mexiletine (Kö 1173) . NZ Med J 8:138-141, 1975;.
10 +
Kosowsky BD, Taylor J, Lown B, et al:  Long-term use of procainamide following acute myocardial infarction . Circulation 47:1204-1210, 1973;.
11 +
Selzer A, Wray HW:  Quinidine syncopeparoxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias . Circulation 30:17-26, 1964;.
12 +
Elliott WC, Stone JM:  β-Adrenergic blocking agents for the treatment of angina pectoris . Prog Cardiovasc Dis 12:83-98, 1969;.
13 +
Fitzgerald JD:  β-Adrenergic blocking drugs: Present position and future development . Acta Cardiol 15( (suppl) ):199, 1972;.
14 +
Stone N, Klein MD, Lown B:  Diphenylhydantoin in the prevention of recurring ventricular tachycardia . Circulation 43:420-427, 1971;.

Letters

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems